A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Hepatology

Volumn 47, Issue 3, 2008, Pages 844-853

  Hsu, Chiun ^a   Hsiung, Chao A ^b   Su, Ih Jen ^b   Hwang, Wei Shou ^c   Wang, Ming Chung ^d   Lin, Sheng Fung ^e   Lin, Tseng Hsi ^f   Hsiao, Hui Hua ^e   Young, Ji Hsiung ^f   Chang, Ming Chih ^g   Liao, Yu Min ^h   Li, Chi Cheng ⁱ   Wu, Hung Bo ^j   Tien, Hwei Fang ^a   Chao, Tsu Yi ^k   Liu, Tsang Wu ^b   Cheng, Ann Lii ^a,b   Chen, Pei Jer ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g MACKAY MEMORIAL HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^j KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^k TRI SERVICE GENERAL HOSPITAL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; LAMIVUDINE; PREDNISOLONE; VINCRISTINE; ANTIVIRUS AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; VIRUS CARRIER; VIRUS REACTIVATION; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEPATITIS B; HUMANS; LAMIVUDINE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 40949125163     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22106     Document Type: Article

References (24)

1. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology 1991;100:182-188.
2. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307.
3. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. HEPATOLOGY 2006;43:209-220.
4. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
5. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B: Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998;339: 61-68.
6. Andreone P, Caraceni P, Grazi GL, Belli L, Milandri GL, Ercolani G, et al. Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 1998;29:985-989.
7. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749.
8. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
9. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-1016.
10. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325.
11. Gutfreund KS, Williams M, George R, Bain VG, Ma MM, Yoshida EM, et al. Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J Hepatol 2000;33:469-475.
12. Clark FL, Drummond MW, Chambers S, Chapman BA, Patton WN. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for highgrade non-Hodgkin's lymphoma. Ann Oncol 1998;9:385-387.
13. Yeo W, Steinberg JL, Tam JS, Chan PK, Leung NW, Lam KC, et al. Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy. J Med Virol 1999;59:263-269.
14. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-1311.
15. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. HEPATOLOGY 2003;37:1320-1328.
16. Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659-666.
17. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244-1253.
18. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
19. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005; 54:1597-1603.
20. Lok AS, McMahon BJ: Chronic hepatitis B. HEPATOLOGY 2004;39:857-861.
21. Lok AS, McMahon BJ: Chronic hepatitis B. HEPATOLOGY 2007;45:507-539.
22. Lok ASF, McMahon BJ: Chronic hepatitis B. HEPATOLOGY 2001;34:1225-1241.
23. Liao CA, Lee CM, Wu HC, Wang MC, Lu SN, Eng HL. Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 2002;116:166-169.
24. Kumar M, Satapathy S, Monga R, Das K, Hissar S, Pande C, et al. A tandomized controlled trial of lamivudine to treat acute hepatitis B. HEPATOLOGY 2007;45:97-101.